Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease. / Frederiksen, Henriette R.; Haukedal, Henriette; Freude, Kristine.

I: BioMed Research International, Bind 2019, 7420189, 2019.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Frederiksen, HR, Haukedal, H & Freude, K 2019, 'Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease', BioMed Research International, bind 2019, 7420189. https://doi.org/10.1155/2019/7420189

APA

Frederiksen, H. R., Haukedal, H., & Freude, K. (2019). Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease. BioMed Research International, 2019, [7420189]. https://doi.org/10.1155/2019/7420189

Vancouver

Frederiksen HR, Haukedal H, Freude K. Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease. BioMed Research International. 2019;2019. 7420189. https://doi.org/10.1155/2019/7420189

Author

Frederiksen, Henriette R. ; Haukedal, Henriette ; Freude, Kristine. / Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease. I: BioMed Research International. 2019 ; Bind 2019.

Bibtex

@article{75246adc701b4dfeae11bfe671126b95,
title = "Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease",
abstract = "Toll-like receptors mediate important cellular immune responses upon activation via various pathogenic stimuli such as bacterial or viral components. The activation and subsequent secretion of cytokines and proinflammatory factors occurs in the whole body including the brain. The subsequent inflammatory response is crucial for the immune system to clear the pathogen(s) from the body via the innate and adaptive immune response. Within the brain, astrocytes, neurons, microglia, and oligodendrocytes all bear unique compositions of Toll-like receptors. Besides pathogens, cellular damage and abnormally folded protein aggregates, such as tau and Amyloid beta peptides, have been shown to activate Toll-like receptors in neurodegenerative diseases such as Alzheimer's disease. This review provides an overview of the different cell type-specific Toll-like receptors of the human brain, their activation mode, and subsequent cellular response, as well as their activation in Alzheimer's disease. Finally, we critically evaluate the therapeutic potential of targeting Toll-like receptors for treatment of Alzheimer's disease as well as discussing the limitation of mouse models in understanding Toll-like receptor function in general and in Alzheimer's disease.",
author = "Frederiksen, {Henriette R.} and Henriette Haukedal and Kristine Freude",
year = "2019",
doi = "10.1155/2019/7420189",
language = "English",
volume = "2019",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - Cell type specific expression of toll-like receptors in human brains and implications in Alzheimer's disease

AU - Frederiksen, Henriette R.

AU - Haukedal, Henriette

AU - Freude, Kristine

PY - 2019

Y1 - 2019

N2 - Toll-like receptors mediate important cellular immune responses upon activation via various pathogenic stimuli such as bacterial or viral components. The activation and subsequent secretion of cytokines and proinflammatory factors occurs in the whole body including the brain. The subsequent inflammatory response is crucial for the immune system to clear the pathogen(s) from the body via the innate and adaptive immune response. Within the brain, astrocytes, neurons, microglia, and oligodendrocytes all bear unique compositions of Toll-like receptors. Besides pathogens, cellular damage and abnormally folded protein aggregates, such as tau and Amyloid beta peptides, have been shown to activate Toll-like receptors in neurodegenerative diseases such as Alzheimer's disease. This review provides an overview of the different cell type-specific Toll-like receptors of the human brain, their activation mode, and subsequent cellular response, as well as their activation in Alzheimer's disease. Finally, we critically evaluate the therapeutic potential of targeting Toll-like receptors for treatment of Alzheimer's disease as well as discussing the limitation of mouse models in understanding Toll-like receptor function in general and in Alzheimer's disease.

AB - Toll-like receptors mediate important cellular immune responses upon activation via various pathogenic stimuli such as bacterial or viral components. The activation and subsequent secretion of cytokines and proinflammatory factors occurs in the whole body including the brain. The subsequent inflammatory response is crucial for the immune system to clear the pathogen(s) from the body via the innate and adaptive immune response. Within the brain, astrocytes, neurons, microglia, and oligodendrocytes all bear unique compositions of Toll-like receptors. Besides pathogens, cellular damage and abnormally folded protein aggregates, such as tau and Amyloid beta peptides, have been shown to activate Toll-like receptors in neurodegenerative diseases such as Alzheimer's disease. This review provides an overview of the different cell type-specific Toll-like receptors of the human brain, their activation mode, and subsequent cellular response, as well as their activation in Alzheimer's disease. Finally, we critically evaluate the therapeutic potential of targeting Toll-like receptors for treatment of Alzheimer's disease as well as discussing the limitation of mouse models in understanding Toll-like receptor function in general and in Alzheimer's disease.

U2 - 10.1155/2019/7420189

DO - 10.1155/2019/7420189

M3 - Review

C2 - 31396533

AN - SCOPUS:85070091042

VL - 2019

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 7420189

ER -

ID: 226492601